Advisornet Financial’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History

Advisornet Financial’s Portfolio MACK Stock Details MACK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-20	Closed	-$247	–	2526
2023 Q3	$247	Hold	20	–	–	﹤0.01%	2109
2023 Q2	$246	Hold	20	–	–	﹤0.01%	2189
2023 Q1	$246	Hold	20	–	–	﹤0.01%	2218
2022 Q4	$229	Hold	20	–	–	﹤0.01%	2191
2022 Q3	$0	Hold	20	–	–	﹤0.01%	2110
2022 Q2	$0	Hold	20	–	–	﹤0.01%	2237
2022 Q1	$0	Hold	20	–	–	﹤0.01%	2298
2021 Q4	$0	Hold	20	–	–	﹤0.01%	2208
2021 Q3	$0	Hold	20	–	–	﹤0.01%	2069
2021 Q2	$0	Hold	20	–	–	﹤0.01%	1910
2021 Q1	$0	Hold	20	–	–	﹤0.01%	1885
2020 Q4	$0	Hold	20	–	–	﹤0.01%	1921
2020 Q3	$0	Buy	+20	New	+$73	﹤0.01%	1971

Other funds holding MACK

WSL

Western Standard LLC Los Angeles, California $190M AUM 40.88% 1-Year Est. Return

Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

MAP

Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Sepio Capital Salt Lake City, Utah $1.84B AUM 18.57% 1-Year Est. Return

SCM

Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Advisornet Financial's MACK Position: Q4 2023 in Review

Advisornet Financial sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q4 2023, closing a stake of 20 shares — an estimated $247 sold.

Advisornet Financial first reported a position in MACK in Q3 2020 and held it in 13 quarters. The position peaked at $247 in Q3 2023. 67 funds tracked by Wall St. Rank hold MACK as of Q4 2023.

Advisornet Financial reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q4 2023 after selling out during the quarter.
Advisornet Financial sold 20 Merrimack Pharmaceuticals, Inc. shares in Q4 2023, an estimated $247.
Advisornet Financial first reported a position in Merrimack Pharmaceuticals, Inc. in Q3 2020 and held it in 13 quarters.
Advisornet Financial's Merrimack Pharmaceuticals, Inc. position peaked at $247 in Q3 2023.
67 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q4 2023.

Based on Advisornet Financial's 13F filing for Q4 2023, filed 19 Jan 2024.